PD-1/PD-L1 inhibitors monotherapy vs. combination therapy in elderly advanced NSCLC: a real-world study and nomogram for survival prognosis
Abstract Background Immunotherapy with PD-1/PD-L1 inhibitors has transformed advanced non-small cell lung cancer (NSCLC) treatment, yet optimal strategies for elderly patients remain uncertain. Elderly patients (≥ 65 years) exhibit immune senescence (e.g., T-cell dysfunction, chronic inflammation),...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2025-07-01
|
| シリーズ: | BMC Pulmonary Medicine |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12890-025-03791-x |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|